First Preclinical Imaging of Primary Cartilage Neoplasm and Its Local Recurrence Using 99mTc-NTP 15-5 Radiotracer

This study on a rat model of grade II chondrosarcoma aimed to determine whether the radiotracer N-(triethylammonium)-3-propyl-[15]ane-N5 radiolabeled with 99mTc (99mTc-NTP 15-5), which binds to cartilage proteoglycans, has pathophysiologic validity for in vivo imaging of cartilage tumoral tissue. Methods: We used 2 experimental approaches with the Swarm chondrosarcoma rat model: that is, a primary paratibial location and local recurrence after intralesional curettage. 99mTc-NTP 15-5 scintigraphy and 99mTc-hydroxymethylenediphosphonate (99mTc-HMDP) scanning were performed at regular intervals during 50 d after tumor implantation in a paratibial location (primary model; n = 12 animals) and after intralesional curettage in a femoral condyle location (recurrence model; n = 9 animals). For each animal, positive scans were analyzed at each time point using the target-to-background ratio (TBR), with the target region of interest delineated over the tumor and the background region of interest over muscle. In each model, the TBR time course was followed against primary tumoral growth or recurrence. Tumor volume was monitored for 2 mo by measuring the 2 perpendicular diameters. At study end, animals were sacrificed for histopathologic analysis. Results: For both models, 99mTc-NTP 15-5 scans showed tracer accumulation at the site of implantation or curettage. For the primary tumor model, the mean TBR was 1.6 ± 0.14 by day 4 after implantation and increased over time as the disease progressed, with a mean TBR of 4.25 ± 0.25 on day 45. For the recurrence model, mean TBR was 3.27 ± 0.24 by day 4 after curettage and increased with recurrence, with a mean value of 5.25 ± 0.49 on day 50. 99mTc-HMDP bone scans were negative for both models throughout the study; at a later stage of the study, an area of 99mTc-HMDP accumulation was seen in the diaphysis of the bone adjacent to the tumor and was attributed to remodeling. Conclusion: These experimental results in 2 preclinical models of grade II chondrosarcoma bring forward data in favor of 99mTc-NTP 15-5 radiotracer for imaging primary growth of chondrosarcoma and its local recurrence after surgery.

[1]  H. Gelderblom,et al.  The clinical approach towards chondrosarcoma. , 2008, The oncologist.

[2]  L. Sarry,et al.  Early detection and monitoring of cartilage alteration in the experimental meniscectomised guinea pig model of osteoarthritis by 99mTc-NTP 15-5 scintigraphy , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  D. Heymann,et al.  Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival , 2006, International journal of cancer.

[4]  F. Bertoni,et al.  Surgical treatment and outcome of conventional pelvic chondrosarcoma. , 2005, The Journal of bone and joint surgery. British volume.

[5]  R. V. Heertum,et al.  18FDG-PET applications for cartilage neoplasms , 2005, Skeletal Radiology.

[6]  K. Nakajima,et al.  Characterization of cartilaginous tumors with201Tl scintigraphy , 2005, Annals of nuclear medicine.

[7]  Francis Y. Lee,et al.  Diagnostic value and limitations of fluorine-18 fluorodeoxyglucose positron emission tomography for cartilaginous tumors of bone. , 2004, The Journal of bone and joint surgery. American volume.

[8]  P. Choong,et al.  The role of thallium-201 and pentavalent dimercaptosuccinic acid for staging cartilaginous tumours , 2004, International seminars in surgical oncology : ISSO.

[9]  W. Brenner,et al.  FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  D. Vanel,et al.  Imaging of chondrosarcomas , 2003, Cancer imaging : the official publication of the International Cancer Imaging Society.

[11]  D. Heymann,et al.  Bone remodelling and tumour grade modifications induced by interactions between bone and swarm rat chondrosarcoma. , 2002, Histology and histopathology.

[12]  H. Hendel,et al.  Utility of Planar Bone Scintigraphy To Distinguish Benign Osteochondromas from Malignant Chondrosarcomas , 2002, Clinical nuclear medicine.

[13]  G. Arsos,et al.  Low-grade chondrosarcomas: a difficult target for radionuclide imaging. Case report and review of the literature. , 2002, European journal of radiology.

[14]  T. Aigner,et al.  Towards a new understanding and classification of chondrogenic neoplasias of the skeleton – biochemistry and cell biology of chondrosarcoma and its variants , 2002, Virchows Archiv.

[15]  T. Aigner,et al.  Prognostic relevance of cell biologic and biochemical features in conventional chondrosarcomas , 2002, Cancer.

[16]  P. Hogendoorn,et al.  Cartilage-forming tumours of bone and soft tissue and their differential diagnosis , 2001 .

[17]  J. Madelmont,et al.  Synthesis of N-quaternary ammonium [3H] and [99mTc]polyazamacrocycles, potential radiotracers for cartilage imaging , 2000 .

[18]  J. Madelmont,et al.  Disposition in rats of N-pyridinium-propyl-cyclam, N-triethylammonium-propyl-cyclam, and N-[Triethylammonium]-3-propyl-[15]ane-N5, potential cartilage imaging agents. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[19]  H J Mankin,et al.  Chondrosarcoma of bone: an assessment of outcome. , 1999, The Journal of bone and joint surgery. American volume.

[20]  C. Masciocchi,et al.  Diagnostic imaging of malignant cartilage tumors. , 1998, European journal of radiology.

[21]  T. Aigner,et al.  Phenotypic diversity of neoplastic chondrocytes and extracellular matrix gene expression in cartilaginous neoplasms. , 1997, The American journal of pathology.

[22]  H. Jacobsson,et al.  Comparison of technetium-99m-MIBI and technetium-99m-tetrofosmin uptake by musculoskeletal sarcomas. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  R. Hicks Nuclear medicine techniques provide unique physiologic characterization of suspected and known soft tissue and bone sarcomas. , 1997, Acta orthopaedica Scandinavica. Supplementum.

[24]  A. Schepper,et al.  Magnetic resonance imaging of cartilaginous tumors: is it useful or necessary? , 1996, Skeletal Radiology.

[25]  Hisataka Kobayashi,et al.  Diagnostic Value of Tc‐99m (V) DMSA for Chondrogenic Tumors With Positive Tc‐99m HMDP Uptake on Bone Scintigraphy , 1995, Clinical nuclear medicine.

[26]  A. Veyre,et al.  Disposition and metabolism of acetylcholinesterase reactivators 2PAM-I, TMB4 and R665 in rats submitted to organophosphate poisoning. , 1991, Xenobiotica; the fate of foreign compounds in biological systems.

[27]  G. Steiner,et al.  Experimental transplantation of the swarm rat chondrosarcoma into bone: Radiological and pathological studies , 1991, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[28]  G. Hascall,et al.  Ultrastructure of the chondrocytes and extracellular matrix of the Swarm rat chondrosarcoma , 1980, The Anatomical record.

[29]  A. Schiller,et al.  The biology of human chondrosarcoma. I. Description of the cases, grading, and biochemical analyses. , 1980, The Journal of bone and joint surgery. American volume.

[30]  L. Díaz de León,et al.  Histological and biochemical studies of a transplantable rat chondrosarcoma. , 1979, Cancer research.

[31]  M. Romsdahl,et al.  Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading , 1977, Cancer.

[32]  T. Oegema,et al.  Isolation and characterization of proteoglycans from the swarm rat chondrosarcoma. , 1975, The Journal of biological chemistry.

[33]  R. Grimer,et al.  Risk factors for survival and local control in chondrosarcoma of bone. , 2002, The Journal of bone and joint surgery. British volume.

[34]  F. Mertens,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .

[35]  A. Veyre,et al.  Joint scintigraphy in rabbits with 99mtc-N-[3-(triethylammonio)propyl]-15ane-N5, a new radiodiagnostic agent for articular cartilage imaging. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  O. Sargin,et al.  Tc-99m tetrofosmin imaging in chondrosarcoma. , 2000, Clinical Nuclear Medicine.

[37]  S. McCarthy Histological Typing of Bone Tumours , 1994 .

[38]  W. Taylor,et al.  Chondrosarcoma: A clinicopathologic and statistical analysis , 1980, Cancer.

[39]  L. J. Roth,et al.  Distribution of hexamethonium and other quaternary ammonium compounds in cartilage. , 1971, The Journal of pharmacology and experimental therapeutics.